You're not high-risk on paper. You're high-risk in every acquirer's model.
General supplement brands — vitamins, minerals, protein, greens, functional foods — technically clear mainstream card processing. In practice, subscription models trigger the same chargeback profile as nutra, and acquirers apply the same 5–9% rolling reserve terms. Stablecoin is the parallel rail that keeps working capital unlocked.
The DTC supplement playbook is chargeback-heavy by design. Cardholders dispute the second billing at 2–4x general e-commerce rates.
Not the peptide tier, but not clean e-commerce either. Working capital stays locked for 90–180 days.
Ad platform enforcement (health claims, disallowed ingredients) creates second-order signals acquirers watch. A Facebook ban precedes a MID review with predictable regularity.
- Wallet-authorized recurring debits — no 'forgot to cancel' dispute vector.
- No rolling reserve on subscription volume.
- Ad-platform enforcement doesn't cascade to rail risk.
- Parallel to card MID — shift only the subscription cohort or run both.
Questions operators in this vertical ask.
You probably shouldn't migrate. Stablecoin is highest-leverage when your subscription chargeback ratio is creeping toward 0.9%, when your reserve is a working-capital constraint, or when you're planning international expansion. If none of those apply, stay on Stripe.
Yes — cohort routing by AOV, geography, or acquisition channel is a common pattern. High-AOV cohorts have the highest per-dispute cost and benefit most from removing chargeback exposure.
Users control their wallet-side recurring authorization. Pause and skip are user actions; the platform reflects them in the schedule.
$ contact --vertical supplements-general